POETIC Partners

Phoenix Children's Hospital

Phoenix Children's Hospital

Phoenix Children's Hospital is one of the 10 largest children's hospitals in the country and provides specialty and sub-specialty inpatient, outpatient, trauma, and emergency care to patients throughout Arizona and other Southwestern states.

The Center for Cancer and Blood Disorders at Phoenix Children's Hospital is the largest pediatric program of its kind in Arizona, providing complete care for children diagnosed with malignancies and hematologic diseases. In 2013, 289 children newly diagnosed with cancer were treated at Phoenix Children's. The Center includes multidisciplinary clinical programs in Leukemia/Lymphoma/Histiocytosis, Solid Tumors, Neuro-oncology, Bone Marrow Transplant, Coagulation Disorders, Hemoglobinopathies, and Survivor/Long Term Follow-up.

The Center's Oncology Research Program supports all phases (I, II, III) of clinical trials with 7 full time research staff members. It is the only hospital in Arizona as well the Southwestern Tristate area which is conducting pediatric phase I and II clinical trials in oncology. There are currently over 100 research studies open at the institution. The program includes a comprehensive Early Drug Development Program with physicians representing each of the clinical specialty areas as well as a full time research nurse and a full time research coordinator. Phoenix Children's is an active participant in multiple clinical trial consortia, including the Children's Oncology Group (COG), Pediatric Oncology Experimental Therapeutics Investigators' Consortium (POETIC), the Neuroblastoma and Medulloblastoma Translation Research Consortium (NMTRC), and the Pediatric Bone Marrow Transplant Consortium (PBMTC).

Additionally, Phoenix Children's Hospital recently established the Ron Matricaria Institute of Molecular Medicine. The goal of the Institute is to develop personalized medicine for patients, targeting specific molecular markers in each patient's cancer cells. This will be closely integrated with the Early Drug Development Program, enabling early clinical trials of this approach using the most promising molecularly targeted agents available.

Little Handprints

by Alexis S., age 3
Acute Lymphocytic Leukemia

Contact Us | Privacy Policy | Terms & Conditions | Members | Board Powered by EmergingMed